Parsaclisib in Japanese patients with relapsed or refractory B‐cell lymphoma (CITADEL‐111): A phase Ib study

Parsaclisib, a potent, selective, next‐generation PI3Kδ inhibitor, has shown clinical benefit in patients with relapsed or refractory B‐cell lymphoma. We undertook a phase Ib study (CITADEL‐111) evaluating safety, pharmacokinetics, and efficacy of parsaclisib in Japanese patients with relapsed or re...

Descripción completa

Detalles Bibliográficos
Autores principales: Fukuhara, Noriko, Suehiro, Youko, Kato, Harumi, Kusumoto, Shigeru, Coronado, Cinthya, Rappold, Erica, Zhao, Wanying, Li, Jia, Gilmartin, Aidan, Izutsu, Koji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9128166/
https://www.ncbi.nlm.nih.gov/pubmed/35201656
http://dx.doi.org/10.1111/cas.15308

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9128166/
https://www.ncbi.nlm.nih.gov/pubmed/35201656
http://dx.doi.org/10.1111/cas.15308

Ejemplares similares